mGlu4 is expressed in the basal ganglia, which suggest a putative target for the treatment of neurological and psychiatric disorders such as Alzheimer’s disease, Parkinson’s disease, anxiety, depression, and schizophrenia [2, 4]. Here, GRM4 is linked to schizophrenia.